Our research

We use behavioural, surveillance, clinical and molecular data to understand drivers for the emergence and re-emergence of STIs and other sexually transmissible infections. This understanding is key for guiding the development and implementation of tailored, timely and effective interventions.

The asymptomatic nature of some STI/BBVs means that a high proportion of affected people remain undiagnosed, resulting in possible onward transmission and increased risk of serious long-term outcomes. Young people, gay, bisexual, and other men who have sex with men (GBMSM), people who inject drugs (PWID), migrants, prisoners and homeless populations are key groups at high risk of undiagnosed STIs/BBVs.

We are developing and evaluating evidence-based STI/BBV interventions and diagnostic/laboratory tools to reach undiagnosed individuals and underserved populations.

We are identifying, understanding and managing factors influencing uptake of healthcare interventions, continuity-in-care and outcomes in persons with STIs/BBVs.

For example, effective treatment requires better understanding of viral genetic factors influencing treatment response, especially for those with rare virus strains which disproportionately affect ethnic minority populations. Additionally, individuals with BBVs/STIs often experience co-morbidities that affect their health and wellbeing.